Charles Schwab Investment Management Inc. Acquires 7,562 Shares of Balchem Co. (NASDAQ:BCPC)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 2.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 361,970 shares of the basic materials company’s stock after buying an additional 7,562 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Balchem were worth $63,707,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in Balchem during the 3rd quarter worth $35,000. Blue Trust Inc. grew its holdings in shares of Balchem by 642.5% during the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 726 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Balchem by 73.4% in the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after buying an additional 356 shares during the period. Private Advisor Group LLC acquired a new position in shares of Balchem in the third quarter valued at approximately $220,000. Finally, TD Asset Management Inc bought a new position in Balchem in the 2nd quarter valued at approximately $200,000. 87.91% of the stock is owned by institutional investors and hedge funds.

Balchem Price Performance

Balchem stock opened at $180.52 on Friday. The stock’s 50 day moving average is $174.33 and its 200 day moving average is $167.26. Balchem Co. has a one year low of $123.88 and a one year high of $186.03. The firm has a market cap of $5.87 billion, a P/E ratio of 48.30, a P/E/G ratio of 5.37 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BCPC shares. HC Wainwright upped their price target on shares of Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, November 4th. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.